Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Alveolar Rhabdomyosarcoma
• MONDO ID: (if available)
• Category:

Research Objectives

Please provide a comprehensive research report on Alveolar Rhabdomyosarcoma covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Disease Characteristics Research Report: Alveolar Rhabdomyosarcoma (ARMS)

Target disease

Alveolar rhabdomyosarcoma (ARMS) is an aggressive rhabdomyosarcoma (RMS) subtype (a malignant mesenchymal tumor showing skeletal muscle differentiation) that occurs primarily in children, adolescents, and young adults and is typically managed with multimodality therapy (systemic chemotherapy plus local control with surgery and/or radiotherapy). (wasti2025childhoodadolescentand pages 2-4, pantelakis2025recentadvanceson pages 1-2)

Table: This table summarizes major 2023–2024 advances in alveolar/fusion-positive rhabdomyosarcoma across diagnostics, biology, prognosis, and therapeutic targeting. It is designed for rapid knowledge-base curation with quantitative findings, evidence type, and source links.

1. Disease information

1.1 Concise overview

RMS is “a mesenchymal tumour showing skeletal muscle differentiation,” and ARMS is one of the major WHO-recognized RMS histologic subtypes. (wasti2025childhoodadolescentand pages 2-4, sankhe2025fusiononcogenesin pages 1-2)

A current clinical–biologic framing is that RMS comprises two dominant molecular groups: fusion-positive (FP) tumors (most often driven by PAX3(7)::FOXO1 fusions and classically associated with alveolar histology) and fusion-negative (FN) tumors (more often embryonal histology and molecularly heterogeneous). (wasti2025childhoodadolescentand pages 2-4)

1.2 Synonyms / alternative names

Commonly used synonyms and near-synonyms in the literature include: - “Alveolar RMS / aRMS” (histology-based) - “Fusion-positive RMS / FP-RMS” (molecularly defined subset; largely overlaps classical ARMS) (wasti2025childhoodadolescentand pages 2-4, sankhe2025fusiononcogenesin pages 1-2)

1.3 Key identifiers (knowledge-base note)

In the retrieved corpus, standardized identifiers (MONDO, MeSH, ICD-10/ICD-11, Orphanet, OMIM) were not explicitly enumerated in-text; therefore, this report cannot provide a verified list from primary sources in context.

1.4 Evidence source type

Most information below is derived from aggregated disease-level resources (reviews, cooperative-group summaries, and prospective/retrospective cohorts) plus primary translational studies in cell lines, mouse models, xenografts, and patient-derived models. (wasti2025childhoodadolescentand pages 2-4, sankhe2025fusiononcogenesin pages 1-2, abbou2023circulatingtumordna pages 1-2, searcy2023pax3foxo1dictatesmyogenic pages 1-2, danielli2024singlecelltranscriptomic pages 1-2, kim2024kdm3binhibitorsdisrupt pages 1-2)

2. Etiology

2.1 Primary causal factors (genetic/mechanistic)

Pathognomonic gene fusions are central causal drivers for most ARMS/FP-RMS: - ARMS frequently harbors PAX3::FOXO1 or PAX7::FOXO1 fusions; one review cites that ~80% of ARMS harbor these fusions. (wasti2025childhoodadolescentand pages 2-4) - In a large RT-PCR fusion-detection cohort of soft tissue tumors, PAX3–FOXO1 was detected in 88.6% (31/35) of ARMS cases. (song2023detectionofvarious pages 1-2)

Direct abstract quote (mechanistic framing): Searcy et al. describe FP-RMS as “driven by the expression of the PAX3-FOXO1 (P3F) fusion oncoprotein” and emphasize that FP-RMS “occurs throughout the body in areas devoid of skeletal muscle,” motivating non-myogenic cell-of-origin models. (searcy2023pax3foxo1dictatesmyogenic pages 1-2)

2.2 Risk factors

Clinical risk/prognostic factors (often used as risk stratifiers) include fusion status, primary site, tumor size, age, extent of disease, nodal status, and metastatic status. (wasti2025childhoodadolescentand pages 1-2, wasti2025childhoodadolescentand pages 2-4)

In a pediatric single-center cohort from India (localized RMS with FOXO1 known, n=140), adverse baseline features were common (e.g., nodal disease ~39–40% and tumors >5 cm in ~56–60%), and in multivariable models, nodal involvement and very large tumor size (>10 cm) were adverse prognostic factors. (ramanathan2023outcomeandprognostic pages 11-13)

Fusion status as a biologic risk factor: PAX3–FOXO1 positivity in RMS was associated with lymph node metastasis and distant metastasis in a multi-center one-step RT-PCR study, and was linked to shorter overall survival. (song2023detectionofvarious pages 1-2)

2.3 Protective factors

No protective genetic variants or environmental protective factors were identified in the retrieved sources.

2.4 Gene–environment interactions

No gene–environment interaction evidence specific to ARMS was identified in the retrieved sources.

3. Phenotypes (clinical presentation)

3.1 Typical clinical phenotype (high-level)

ARMS is a malignant soft tissue tumor that can occur in multiple anatomic sites; one case-based review notes ARMS is prevalent in adolescents and “usually develops in the extremities and can also involve the trunk, perineum, and pelvis.” (song2023detectionofvarious pages 1-2)

3.2 Phenotype characteristics (structured suggestions)

Evidence in the retrieved corpus is strongest for oncologic phenotype (local invasion, nodal/distant metastasis) rather than symptom frequency catalogs. The following HPO term suggestions are therefore provided as knowledge-base candidates (not all have frequencies in the cited sources): - Mass of soft tissue (HP:0001417) - Regional lymph node metastasis (HP:0032726) - Distant metastasis (HP:0002665) - Pain (HP:0012531) and swelling (HP:0000984) as common sarcoma presentations (not quantified in retrieved sources)

3.3 Quality of life impact

No ARMS-specific QoL instrument statistics were identified in the retrieved sources.

4. Genetic / molecular information

4.1 Causal genes / chromosomal abnormalities

Core causal alterations (somatic): - PAX3::FOXO1 and PAX7::FOXO1 fusions define FP-RMS/ARMS biology and are key diagnostic and prognostic markers. (wasti2025childhoodadolescentand pages 2-4)

Other poor-risk variants (contextual): Cooperative-group summaries note additional poor-risk variants such as MYOD1 and TP53 in RMS risk stratification discussions. (wasti2025childhoodadolescentand pages 1-2)

4.2 Variant type/class and origin

• The canonical ARMS alterations are structural rearrangements (chromosomal translocations) yielding fusion transcription factors. (obeidin2023what’snewin pages 2-3, obeidin2023what’snewin pages 1-2)
• These are generally somatic drivers (germline predisposition was not specifically established for ARMS in the retrieved sources).

4.3 Epigenetic dependencies and regulators (mechanistic genetics)

Recent mechanistic work underscores epigenetic and transcriptional dependencies in FP-RMS: - Searcy et al. report that PAX3-FOXO1 “functions as a pioneer transcription factor” and “activates myogenic super-enhancers that define RMS cell identity including MYOD1, MYOGENIN and MYCN.” (searcy2023pax3foxo1dictatesmyogenic pages 1-2) - Kim et al. identify small-molecule KDM3B-selective inhibitors (P3FI-63/P3FI-90) that downregulate PAX3-FOXO1 transcriptional output and alter chromatin-associated features at PAX3-FOXO1 sites; P3FI-63 inhibits KDM3B with IC50 = 7 µM. (kim2024kdm3binhibitorsdisrupt pages 2-3)

5. Environmental information

No disease-specific environmental, lifestyle, toxin, radiation, or infectious causal factors for ARMS were identified in the retrieved sources.

6. Mechanism / pathophysiology

6.1 Causal chain (current synthesis)

1) Initiating genomic event: a PAX3/7::FOXO1 fusion forms an aberrant transcription factor in FP-RMS/ARMS. (wasti2025childhoodadolescentand pages 2-4, searcy2023pax3foxo1dictatesmyogenic pages 1-2) 2) Transcriptional reprogramming: PAX3-FOXO1 can reprogram non-myogenic progenitors; Searcy et al. demonstrate PAX3-FOXO1 “reprograms mouse and human endothelial progenitors to FP-RMS.” (searcy2023pax3foxo1dictatesmyogenic pages 1-2) 3) Epigenetic remodeling and super-enhancer activation: PAX3-FOXO1 “activates myogenic super-enhancers” and establishes RMS cell identity programs. (searcy2023pax3foxo1dictatesmyogenic pages 1-2, searcy2023pax3foxo1dictatesmyogenic media 14ad6904) 4) Cell-state heterogeneity and therapy resistance: single-cell profiling identifies dominant RMS cell states and shows FP-RMS can include tumor-acquired, non-developmental programs (e.g., a neuronal state) that may persist after therapy. (danielli2024singlecelltranscriptomic pages 1-2) 5) Clinical phenotype: aggressive local behavior and higher propensity for metastasis and poor outcomes in fusion-positive disease cohorts. (wasti2025childhoodadolescentand pages 2-4, song2023detectionofvarious pages 1-2)

6.2 2023–2024 mechanistic developments (selected)

• Cell of origin and lineage plasticity (Nov 2023, Nature Communications): Searcy et al. generate an endothelial-driven FP-RMS model and report lineage-traced myogenic stem-cell features; for example, in their ACP model “of 940 Tom+ cells counted in the SCM … 30% co-localized with PAX7.” (searcy2023pax3foxo1dictatesmyogenic pages 1-2, searcy2023pax3foxo1dictatesmyogenic media a3da86b9)
• Single-cell atlas of RMS (Jul 2024, Nature Communications): Danielli et al. integrate 72 datasets and identify four dominant muscle-lineage cell states (progenitor, proliferative, differentiated, ground), with some FP-RMS tumors containing tumor-acquired neuronal cell states not observed in normal myogenesis. (danielli2024singlecelltranscriptomic pages 1-2)
• Epigenetic drug discovery (Feb 2024, Nature Communications): Kim et al. screen 62,643 compounds and develop KDM3B-selective inhibitors that suppress FP-RMS growth in vivo; e.g., P3FI-90 delayed tumor progression in a metastatic IV xenograft model (p=0.0016) and reduced tumor volume in an orthotopic intramuscular model (p=0.0046). (kim2024kdm3binhibitorsdisrupt pages 1-2, kim2024kdm3binhibitorsdisrupt pages 10-12)

6.3 Suggested ontology terms (mechanisms)

GO biological process (suggestions): - Regulation of transcription by RNA polymerase II (GO:0006357) - Chromatin organization (GO:0006325) - Skeletal muscle cell differentiation (GO:0035914) - Cell cycle process (GO:0022402) - Apoptotic process (GO:0006915)

Cell types (CL suggestions): - Endothelial cell (CL:0000115) (supported conceptually by endothelial progenitor reprogramming) (searcy2023pax3foxo1dictatesmyogenic pages 1-2) - Myoblast / skeletal muscle precursor (e.g., CL:0000056 myoblast)

7. Anatomical structures affected

7.1 Organ/tissue level

ARMS is a soft tissue sarcoma that frequently arises in skeletal muscle-associated soft tissues but can occur at sites without skeletal muscle, consistent with reprogramming models and broad anatomic distribution. (searcy2023pax3foxo1dictatesmyogenic pages 1-2)

Common sites in cited literature: extremities, trunk, perineum/pelvis. (song2023detectionofvarious pages 1-2)

7.2 UBERON suggestions

• Skeletal muscle tissue (UBERON:0001134)
• Pelvis (UBERON:0001270)
• Lymph node (UBERON:0000029)

8. Temporal development

8.1 Onset

RMS is predominantly pediatric/adolescent; ARMS is noted as prevalent in adolescents in clinical literature. (song2023detectionofvarious pages 1-2)

8.2 Progression

High-risk biology is linked to fusion-positive status, nodal involvement, and metastatic presentation; relapses commonly occur within ~2 years in one cohort (median relapse ~18 months). (ramanathan2023outcomeandprognostic pages 4-7)

9. Inheritance and population

9.1 Epidemiology (disease burden)

RMS accounts for ~3% of childhood cancers, with ~400–500 cases diagnosed annually in the United States (all RMS). (sankhe2025fusiononcogenesin pages 1-2)

9.2 Demographics (selected)

In a localized RMS cohort with FOXO1 status known (n=140), the median age was 4.4 years and the sex ratio was ~2.1:1 (boys:girls). (ramanathan2023outcomeandprognostic pages 2-4)

9.3 Fusion prevalence in clinical cohorts

• Cooperative-group synthesis: ~80% of ARMS harbor PAX3/7::FOXO1 fusions. (wasti2025childhoodadolescentand pages 2-4)
• Single-center cohort (localized RMS with fusion known): among ARMS, 25/49 (51%) were FOXO1 fusion-positive (PAX3–FOXO1 or PAX7–FOXO1). (ramanathan2023outcomeandprognostic pages 4-7)
• Multi-center diagnostic RT-PCR cohort: PAX3–FOXO1 in 31/35 ARMS (88.6%). (song2023detectionofvarious pages 1-2)

(These differences likely reflect case mix, assay targets, and classification differences across cohorts; the retrieved sources did not provide a harmonized prevalence estimate.)

10. Diagnostics

10.1 Histopathology and immunohistochemistry (IHC)

Molecular testing is frequently needed in soft tissue tumor diagnosis; a 2023 guideline-style review emphasizes that in rhabdomyoblastic tumors molecular confirmation can be important to distinguish embryonal from alveolar RMS when morphology/IHC are insufficient, with FOXO1 fusions serving as definitive classification markers. (obeidin2023what’snewin pages 2-3)

10.2 Molecular testing approaches (2023 best-practice themes)

A morphology-driven, tiered diagnostic strategy is recommended across sarcoma molecular-testing guidance: - FISH remains useful, including break-apart probes when a fusion partner is unknown; - RT-PCR can detect known fusion breakpoints but “generally lacks the ability to detect new fusion partners”; - RNA-based NGS (hybrid-capture or anchored multiplex PCR) is increasingly adopted for sensitive fusion detection and novel partner discovery; methylation profiling is emerging for classification. (obeidin2023what’snewin pages 1-2)

10.3 ARMS-specific fusion testing performance data

Song et al. provide real-world performance data in FFPE tissues: - Among evaluable samples (n=213), overall fusion-positive rate 60% (133/213). - In ARMS, PAX3–FOXO1 detected in 88.6% (31/35). - FISH concordant with one-step RT-PCR in 18/18 tested cases. These findings support one-step RT-PCR as an accurate, low-cost fusion assay in routine settings. (song2023detectionofvarious pages 1-2)

10.4 Liquid biopsy (2023 clinical implementation direction)

Abbou et al. (COG biorepository; intermediate-risk RMS) show that baseline ctDNA is detectable and prognostic: - In FP-RMS, translocation-based ctDNA detection identified ctDNA in 27/49 (55%). - Outcomes were worse with baseline ctDNA detection (FP-RMS OS 39.2% vs 75%; EFS 37% vs 70% for ctDNA-positive vs negative). (abbou2023circulatingtumordna pages 1-2)

Direct abstract quote (purpose and conclusion excerpts): The study states, “We sought to evaluate strategies for identifying circulating tumor DNA (ctDNA) in IR RMS and to determine whether ctDNA detection before therapy is associated with outcome,” and concludes that “baseline ctDNA detection is feasible and is prognostic in IR RMS.” (abbou2023circulatingtumordna pages 1-2)

10.5 Differential diagnosis (high-level)

ARMS frequently falls within the “small round blue cell tumor” differential; the retrieved sources emphasize molecular testing (FISH/RT-PCR/NGS) to resolve histologic overlap across entities. (obeidin2023what’snewin pages 1-2, choi2023therecentadvances pages 1-2)

11. Outcome / prognosis

11.1 Survival statistics (selected)

• In a cooperative-group synthesis, fusion-positive tumors with locoregional nodal involvement (N1) are a recognized poor-risk group; cited 5-year OS 45.5% and 5-year EFS 43%. (wasti2025childhoodadolescentand pages 2-4)
• A broad RMS epidemiology review reports risk-group survival ranges (all RMS): low-risk ~70–90%, intermediate 50–70%, high-risk 20–30%, and highlights worse outcomes in fusion-positive disease. (pantelakis2025recentadvanceson pages 1-2)

11.2 Prognostic factors (reproducible across cohorts)

Prognosis is strongly influenced by fusion status plus classic clinicopathologic factors including tumor site, size, nodal status, metastatic status, extent of resection/residual disease, and age. (wasti2025childhoodadolescentand pages 1-2, wasti2025childhoodadolescentand pages 2-4)

11.3 Recent prognostic biomarker: ctDNA

Baseline ctDNA detection adds prognostic resolution within intermediate-risk RMS, with large differences in OS/EFS by ctDNA status as reported above. (abbou2023circulatingtumordna pages 1-2)

12. Treatment

12.1 Standard of care (real-world implementation)

Standard RMS care remains multimodality: systemic multi-agent chemotherapy combined with surgery and/or radiotherapy for local control, delivered through risk-stratified cooperative-group protocols. (wasti2025childhoodadolescentand pages 2-4, pantelakis2025recentadvanceson pages 1-2)

12.2 Risk stratification increasingly incorporates fusion status

Fusion status is emphasized as a key prognostic biomarker used alongside clinical features to guide therapy intensity and duration; algorithms are evolving as molecular biology and genomics advance. (wasti2025childhoodadolescentand pages 1-2, wasti2025childhoodadolescentand pages 2-4)

12.3 Selected clinical trials (with real-world identifiers)

Relapsed/refractory RMS (includes ARMS): - NCT01222715 (start 2010; completed 2015): randomized phase II trial of vinorelbine + cyclophosphamide combined with either bevacizumab or temsirolimus; cycles every 21 days up to 12 courses; primary objectives included feasibility and estimation/comparison of EFS. (NCT01222715 chunk 1) - NCT03041701 (start 2017; terminated): open-label phase I/II of ganitumab (anti–IGF-1R) plus dasatinib (SFK inhibitor) in relapsed/refractory embryonal or alveolar RMS; terminated due to drug availability; phase II closed early. (NCT03041701 chunk 1) - NCT02867592 (start 2017; active-not-recruiting): phase II single-group cabozantinib (oral, continuous dosing) in children/young adults with refractory/recurrent solid tumors including rhabdomyosarcoma; primary endpoint objective response rate by RECIST v1.1 for non-osteosarcoma strata. (NCT02867592 chunk 1)

High-risk RMS upfront strategy refinement: - NCT04994132 / ARST2031 (start 2021; active-not-recruiting; estimated primary completion 2026): phase III comparing VINO-AC vs VAC induction approaches, followed by vinorelbine + oral cyclophosphamide maintenance for 24 weeks; includes correlative ctDNA and genomic prognostic objectives. (NCT04994132 chunk 1)

12.4 MAXO (Medical Action Ontology) suggestions

• Chemotherapy (MAXO:0000058)
• Surgical resection (MAXO:0000011)
• Radiotherapy (MAXO:0000014)
• Molecular genetic testing (MAXO:0001001)
• Liquid biopsy / ctDNA testing (MAXO suggestion; not validated in retrieved sources)

13. Prevention

No primary prevention strategies specific to ARMS were identified in the retrieved sources. Given the dominant role of somatic fusion oncogenes and the rarity of the disease, prevention focuses pragmatically on early diagnosis, referral to sarcoma centers, and enrollment in cooperative-group protocols (not quantitatively evaluated in retrieved sources).

14. Other species / natural disease

No naturally occurring ARMS analogs in non-human species were identified in the retrieved sources.

15. Model organisms and experimental models

Recent studies emphasize diverse model systems: - Genetically engineered mouse models and lineage tracing: Searcy et al. develop an endothelial-driven PAX3-FOXO1 model and demonstrate reprogramming toward myogenic stem-like states and FP-RMS formation. (searcy2023pax3foxo1dictatesmyogenic pages 1-2, searcy2023pax3foxo1dictatesmyogenic media a3da86b9) - Human iPSC-based developmental models: PAX3-FOXO1 expression in TP53-null iPSCs redirects differentiation and yields FP-RMS tumors in immunocompromised mice. (searcy2023pax3foxo1dictatesmyogenic pages 1-2) - Patient-derived xenografts and single-cell atlases: Danielli et al. include patient tumors, PDXs, primary cultures, and cell lines in a unified single-cell analysis, enabling cross-model comparisons of cell states and therapy-associated changes. (danielli2024singlecelltranscriptomic pages 1-2)

Limitations noted implicitly by these approaches include model dependence on engineered genetic contexts (e.g., TP53-null backgrounds), and the challenge of faithfully capturing therapy-induced and tumor-acquired states in vitro.

Expert synthesis / analysis (authoritative perspectives)

Across cooperative-group summaries, fusion status is consistently treated as a cornerstone biomarker that should be integrated into diagnostics and risk stratification, because it captures biology linked to adverse outcome and can refine treatment intensity. (wasti2025childhoodadolescentand pages 1-2, wasti2025childhoodadolescentand pages 2-4)

The 2023–2024 translational literature increasingly converges on the idea that FP-RMS is a transcriptionally and epigenetically addicted fusion-driven cancer, where vulnerabilities may lie in chromatin regulators (e.g., KDM dependencies) and in measurable tumor burden via ctDNA, rather than in high mutational burden targets. This framing is supported by direct functional studies (KDM3B inhibitors), developmental reprogramming models (endothelial progenitor origin), and clinical biomarker work (ctDNA prognostic value). (abbou2023circulatingtumordna pages 1-2, searcy2023pax3foxo1dictatesmyogenic pages 1-2, kim2024kdm3binhibitorsdisrupt pages 10-12)

References (URLs and publication dates)

• Abbou S. et al. Journal of Clinical Oncology (May 2023). “Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group.” https://doi.org/10.1200/jco.22.00409 (abbou2023circulatingtumordna pages 1-2)
• Song L. et al. Frontiers in Cell and Developmental Biology (Aug 2023). “Detection of various fusion genes by one-step RT-PCR…” https://doi.org/10.3389/fcell.2023.1214262 (song2023detectionofvarious pages 1-2)
• Searcy M.B. et al. Nature Communications (Nov 2023). “PAX3-FOXO1 dictates myogenic reprogramming…” https://doi.org/10.1038/s41467-023-43044-1 (searcy2023pax3foxo1dictatesmyogenic pages 1-2)
• Kim Y.Y. et al. Nature Communications (Feb 2024). “KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1…” https://doi.org/10.1038/s41467-024-45902-y (kim2024kdm3binhibitorsdisrupt pages 1-2)
• Danielli S.G. et al. Nature Communications (Jul 2024). “Single cell transcriptomic profiling identifies…” https://doi.org/10.1038/s41467-024-50527-2 (danielli2024singlecelltranscriptomic pages 1-2)
• Obeidin F. Journal of Pathology and Translational Medicine (May 2023). “What’s new in bone and soft tissue pathology 2023: guidelines for molecular testing.” https://doi.org/10.4132/jptm.2023.03.20 (obeidin2023what’snewin pages 1-2)
• ClinicalTrials.gov: NCT01222715 (2010 record; completed 2015). https://clinicaltrials.gov/study/NCT01222715 (NCT01222715 chunk 1)
• ClinicalTrials.gov: NCT03041701 (2017 record; terminated). https://clinicaltrials.gov/study/NCT03041701 (NCT03041701 chunk 1)
• ClinicalTrials.gov: NCT02867592 (2017 record; active-not-recruiting). https://clinicaltrials.gov/study/NCT02867592 (NCT02867592 chunk 1)
• ClinicalTrials.gov: NCT04994132 (2021 record; active-not-recruiting). https://clinicaltrials.gov/study/NCT04994132 (NCT04994132 chunk 1)

References

1. (wasti2025childhoodadolescentand pages 2-4): Ajla T. Wasti, Gianni Bisogno, Raquel Hladun, Anne-Sophie Defachelles, Michela Casanova, Willemijn B. Breunis, Susanne A. Gatz, Reineke A. Schoot, Andrea Ferrari, Meriel Jenney, Rita Alaggio, Raquel Davila Fajardo, Sheila Terwisscha van Scheltinga, Janet Shipley, Michael Torsten Meister, Rick R. van Rijn, John Anderson, Monika Sparber-Sauer, Julia C. Chisholm, and Johannes H. M. Merks. Childhood, adolescent and young adult poor-prognosis rhabdomyosarcoma. Cancers, 17:3100, Sep 2025. URL: https://doi.org/10.3390/cancers17193100, doi:10.3390/cancers17193100. This article has 1 citations.

2. (pantelakis2025recentadvanceson pages 1-2): Konstantinos Pantelakis and George I. Lambrou. Recent advances on the biology, prognosis and treatment of rhabdomyosarcoma. Journal of Research and Practice on the Musculoskeletal System, 9:46-53, Jun 2025. URL: https://doi.org/10.22540/jrpms-09-046, doi:10.22540/jrpms-09-046. This article has 0 citations.

3. (abbou2023circulatingtumordna pages 1-2): Samuel Abbou, Kelly Klega, Junko Tsuji, Mohammad Tanhaemami, David Hall, Donald A. Barkauskas, Mark D. Krailo, Carrie Cibulskis, Anwesha Nag, Aaron R. Thorner, Samuel Pollock, Alma Imamovic-Tuco, Jack F. Shern, Steven G. DuBois, Rajkumar Venkatramani, Douglas S. Hawkins, and Brian D. Crompton. Circulating tumor dna is prognostic in intermediate-risk rhabdomyosarcoma: a report from the children's oncology group. Journal of Clinical Oncology, 41:2382-2393, May 2023. URL: https://doi.org/10.1200/jco.22.00409, doi:10.1200/jco.22.00409. This article has 36 citations and is from a highest quality peer-reviewed journal.

4. (searcy2023pax3foxo1dictatesmyogenic pages 1-2): Madeline B. Searcy, Randolph K. Larsen, Bradley T. Stevens, Yang Zhang, Hongjian Jin, Catherine J. Drummond, Casey G. Langdon, Katherine E. Gadek, Kyna Vuong, Kristin B. Reed, Matthew R. Garcia, Beisi Xu, Darden W. Kimbrough, Grace E. Adkins, Nadhir Djekidel, Shaina N. Porter, Patrick A. Schreiner, Shondra M. Pruett-Miller, Brian J. Abraham, Jerold E. Rehg, and Mark E. Hatley. Pax3-foxo1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors. Nature Communications, Nov 2023. URL: https://doi.org/10.1038/s41467-023-43044-1, doi:10.1038/s41467-023-43044-1. This article has 36 citations and is from a highest quality peer-reviewed journal.

5. (searcy2023pax3foxo1dictatesmyogenic media a3da86b9): Madeline B. Searcy, Randolph K. Larsen, Bradley T. Stevens, Yang Zhang, Hongjian Jin, Catherine J. Drummond, Casey G. Langdon, Katherine E. Gadek, Kyna Vuong, Kristin B. Reed, Matthew R. Garcia, Beisi Xu, Darden W. Kimbrough, Grace E. Adkins, Nadhir Djekidel, Shaina N. Porter, Patrick A. Schreiner, Shondra M. Pruett-Miller, Brian J. Abraham, Jerold E. Rehg, and Mark E. Hatley. Pax3-foxo1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors. Nature Communications, Nov 2023. URL: https://doi.org/10.1038/s41467-023-43044-1, doi:10.1038/s41467-023-43044-1. This article has 36 citations and is from a highest quality peer-reviewed journal.

6. (danielli2024singlecelltranscriptomic pages 1-2): Sara G. Danielli, Yun Wei, Michael A. Dyer, Elizabeth Stewart, Heather Sheppard, Marco Wachtel, Beat W. Schäfer, Anand G. Patel, and David M. Langenau. Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50527-2, doi:10.1038/s41467-024-50527-2. This article has 39 citations and is from a highest quality peer-reviewed journal.

7. (kim2024kdm3binhibitorsdisrupt pages 1-2): Yong Yean Kim, Berkley E. Gryder, Ranuka Sinniah, Megan L. Peach, Jack F. Shern, Abdalla Abdelmaksoud, Silvia Pomella, Girma M. Woldemichael, Benjamin Z. Stanton, David Milewski, Joseph J. Barchi, John S. Schneekloth, Raj Chari, Joshua T. Kowalczyk, Shilpa R. Shenoy, Jason R. Evans, Young K. Song, Chaoyu Wang, Xinyu Wen, Hsien-Chao Chou, Vineela Gangalapudi, Dominic Esposito, Jane Jones, Lauren Procter, Maura O’Neill, Lisa M. Jenkins, Nadya I. Tarasova, Jun S. Wei, James B. McMahon, Barry R. O’Keefe, Robert G. Hawley, and Javed Khan. Kdm3b inhibitors disrupt the oncogenic activity of pax3-foxo1 in fusion-positive rhabdomyosarcoma. Nature Communications, Feb 2024. URL: https://doi.org/10.1038/s41467-024-45902-y, doi:10.1038/s41467-024-45902-y. This article has 22 citations and is from a highest quality peer-reviewed journal.

8. (kim2024kdm3binhibitorsdisrupt pages 10-12): Yong Yean Kim, Berkley E. Gryder, Ranuka Sinniah, Megan L. Peach, Jack F. Shern, Abdalla Abdelmaksoud, Silvia Pomella, Girma M. Woldemichael, Benjamin Z. Stanton, David Milewski, Joseph J. Barchi, John S. Schneekloth, Raj Chari, Joshua T. Kowalczyk, Shilpa R. Shenoy, Jason R. Evans, Young K. Song, Chaoyu Wang, Xinyu Wen, Hsien-Chao Chou, Vineela Gangalapudi, Dominic Esposito, Jane Jones, Lauren Procter, Maura O’Neill, Lisa M. Jenkins, Nadya I. Tarasova, Jun S. Wei, James B. McMahon, Barry R. O’Keefe, Robert G. Hawley, and Javed Khan. Kdm3b inhibitors disrupt the oncogenic activity of pax3-foxo1 in fusion-positive rhabdomyosarcoma. Nature Communications, Feb 2024. URL: https://doi.org/10.1038/s41467-024-45902-y, doi:10.1038/s41467-024-45902-y. This article has 22 citations and is from a highest quality peer-reviewed journal.

9. (kim2024kdm3binhibitorsdisrupt pages 2-3): Yong Yean Kim, Berkley E. Gryder, Ranuka Sinniah, Megan L. Peach, Jack F. Shern, Abdalla Abdelmaksoud, Silvia Pomella, Girma M. Woldemichael, Benjamin Z. Stanton, David Milewski, Joseph J. Barchi, John S. Schneekloth, Raj Chari, Joshua T. Kowalczyk, Shilpa R. Shenoy, Jason R. Evans, Young K. Song, Chaoyu Wang, Xinyu Wen, Hsien-Chao Chou, Vineela Gangalapudi, Dominic Esposito, Jane Jones, Lauren Procter, Maura O’Neill, Lisa M. Jenkins, Nadya I. Tarasova, Jun S. Wei, James B. McMahon, Barry R. O’Keefe, Robert G. Hawley, and Javed Khan. Kdm3b inhibitors disrupt the oncogenic activity of pax3-foxo1 in fusion-positive rhabdomyosarcoma. Nature Communications, Feb 2024. URL: https://doi.org/10.1038/s41467-024-45902-y, doi:10.1038/s41467-024-45902-y. This article has 22 citations and is from a highest quality peer-reviewed journal.

10. (song2023detectionofvarious pages 1-2): Lingxie Song, Ying Zhang, Yuanyuan Wang, Qingxin Xia, Dandan Guo, Jiachen Cao, Xin Xin, Haoyue Cheng, Chunxia Liu, Xingyuan Jia, and Feng Li. Detection of various fusion genes by one-step rt-pcr and the association with clinicopathological features in 242 cases of soft tissue tumor. Frontiers in Cell and Developmental Biology, Aug 2023. URL: https://doi.org/10.3389/fcell.2023.1214262, doi:10.3389/fcell.2023.1214262. This article has 6 citations.

11. (sankhe2025fusiononcogenesin pages 1-2): Chinmay S. Sankhe, Lisa Hall, and Genevieve C. Kendall. Fusion oncogenes in rhabdomyosarcoma: model systems, mechanisms of tumorigenesis, and therapeutic implications. Frontiers in Oncology, Jun 2025. URL: https://doi.org/10.3389/fonc.2025.1570070, doi:10.3389/fonc.2025.1570070. This article has 7 citations.

12. (wasti2025childhoodadolescentand pages 1-2): Ajla T. Wasti, Gianni Bisogno, Raquel Hladun, Anne-Sophie Defachelles, Michela Casanova, Willemijn B. Breunis, Susanne A. Gatz, Reineke A. Schoot, Andrea Ferrari, Meriel Jenney, Rita Alaggio, Raquel Davila Fajardo, Sheila Terwisscha van Scheltinga, Janet Shipley, Michael Torsten Meister, Rick R. van Rijn, John Anderson, Monika Sparber-Sauer, Julia C. Chisholm, and Johannes H. M. Merks. Childhood, adolescent and young adult poor-prognosis rhabdomyosarcoma. Cancers, 17:3100, Sep 2025. URL: https://doi.org/10.3390/cancers17193100, doi:10.3390/cancers17193100. This article has 1 citations.

13. (ramanathan2023outcomeandprognostic pages 11-13): Subramaniam Ramanathan, Sneha Sisodiya, Omshree Shetty, Maya Prasad, Badira C Parambil, Sneha Shah, Mukta Ramadwar, Nehal Khanna, Siddhartha Laskar, Sajid Qureshi, Tushar Vora, and Girish Chinnaswamy. Outcome and prognostic variables in childhood rhabdomyosarcoma (rms) with emphasis on impact of foxo1 fusions in non-metastatic rms: experience from a tertiary cancer centre in india. ecancermedicalscience, Apr 2023. URL: https://doi.org/10.3332/ecancer.2023.1539, doi:10.3332/ecancer.2023.1539. This article has 5 citations and is from a peer-reviewed journal.

14. (obeidin2023what’snewin pages 2-3): Farres Obeidin. What’s new in bone and soft tissue pathology 2023: guidelines for molecular testing. Journal of Pathology and Translational Medicine, 57:184-187, May 2023. URL: https://doi.org/10.4132/jptm.2023.03.20, doi:10.4132/jptm.2023.03.20. This article has 5 citations.

15. (obeidin2023what’snewin pages 1-2): Farres Obeidin. What’s new in bone and soft tissue pathology 2023: guidelines for molecular testing. Journal of Pathology and Translational Medicine, 57:184-187, May 2023. URL: https://doi.org/10.4132/jptm.2023.03.20, doi:10.4132/jptm.2023.03.20. This article has 5 citations.

16. (searcy2023pax3foxo1dictatesmyogenic media 14ad6904): Madeline B. Searcy, Randolph K. Larsen, Bradley T. Stevens, Yang Zhang, Hongjian Jin, Catherine J. Drummond, Casey G. Langdon, Katherine E. Gadek, Kyna Vuong, Kristin B. Reed, Matthew R. Garcia, Beisi Xu, Darden W. Kimbrough, Grace E. Adkins, Nadhir Djekidel, Shaina N. Porter, Patrick A. Schreiner, Shondra M. Pruett-Miller, Brian J. Abraham, Jerold E. Rehg, and Mark E. Hatley. Pax3-foxo1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors. Nature Communications, Nov 2023. URL: https://doi.org/10.1038/s41467-023-43044-1, doi:10.1038/s41467-023-43044-1. This article has 36 citations and is from a highest quality peer-reviewed journal.

17. (ramanathan2023outcomeandprognostic pages 4-7): Subramaniam Ramanathan, Sneha Sisodiya, Omshree Shetty, Maya Prasad, Badira C Parambil, Sneha Shah, Mukta Ramadwar, Nehal Khanna, Siddhartha Laskar, Sajid Qureshi, Tushar Vora, and Girish Chinnaswamy. Outcome and prognostic variables in childhood rhabdomyosarcoma (rms) with emphasis on impact of foxo1 fusions in non-metastatic rms: experience from a tertiary cancer centre in india. ecancermedicalscience, Apr 2023. URL: https://doi.org/10.3332/ecancer.2023.1539, doi:10.3332/ecancer.2023.1539. This article has 5 citations and is from a peer-reviewed journal.

18. (ramanathan2023outcomeandprognostic pages 2-4): Subramaniam Ramanathan, Sneha Sisodiya, Omshree Shetty, Maya Prasad, Badira C Parambil, Sneha Shah, Mukta Ramadwar, Nehal Khanna, Siddhartha Laskar, Sajid Qureshi, Tushar Vora, and Girish Chinnaswamy. Outcome and prognostic variables in childhood rhabdomyosarcoma (rms) with emphasis on impact of foxo1 fusions in non-metastatic rms: experience from a tertiary cancer centre in india. ecancermedicalscience, Apr 2023. URL: https://doi.org/10.3332/ecancer.2023.1539, doi:10.3332/ecancer.2023.1539. This article has 5 citations and is from a peer-reviewed journal.

19. (choi2023therecentadvances pages 1-2): Joon Hyuk Choi and Jae Y. Ro. The recent advances in molecular diagnosis of soft tissue tumors. International Journal of Molecular Sciences, 24:5934, Mar 2023. URL: https://doi.org/10.3390/ijms24065934, doi:10.3390/ijms24065934. This article has 32 citations.

20. (NCT01222715 chunk 1): Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma. National Cancer Institute (NCI). 2010. ClinicalTrials.gov Identifier: NCT01222715

21. (NCT03041701 chunk 1): Christine Heske, M.D.. Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma. National Cancer Institute (NCI). 2017. ClinicalTrials.gov Identifier: NCT03041701

22. (NCT02867592 chunk 1): Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors. National Cancer Institute (NCI). 2017. ClinicalTrials.gov Identifier: NCT02867592

23. (NCT04994132 chunk 1): A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma. Children's Oncology Group. 2021. ClinicalTrials.gov Identifier: NCT04994132

1. Disease Information

Overview

Alveolar rhabdomyosarcoma (ARMS) is a high-grade malignant neoplasm of skeletal muscle lineage. It belongs to the broader family of rhabdomyosarcomas, which are the most common soft tissue sarcomas in children and adolescents. ARMS accounts for approximately 20–25% of all RMS cases, with the remainder primarily comprising embryonal rhabdomyosarcoma (ERMS). The name "alveolar" derives from its microscopic resemblance to lung alveoli, with clusters of small round blue cells separated by fibrovascular septa.

Key Identifiers

Synonyms and Alternative Names

• Alveolar RMS (ARMS)
• Fusion-positive rhabdomyosarcoma (FP-RMS) — when harboring PAX3/7-FOXO1 fusions
• RMA (Rhabdomyosarcoma, alveolar type)
• PAX-FOXO1 fusion-positive rhabdomyosarcoma

Information Source

This report synthesizes information from aggregated disease-level resources including OMIM, Orphanet, SEER databases, Children's Oncology Group (COG) clinical trials, European paediatric Soft tissue sarcoma Study Group (EpSSG) trials, and primary literature from PubMed.

2. Etiology

Disease Causal Factors

ARMS is fundamentally a genetic/molecular disease driven by somatic chromosomal translocations. The primary causal events are:

1. t(2;13)(q35;q14) — producing the PAX3-FOXO1 fusion gene (~60% of ARMS)
2. t(1;13)(p36;q14) — producing the PAX7-FOXO1 fusion gene (~20% of ARMS)

These translocations fuse the DNA-binding domains of PAX3 or PAX7 (paired box transcription factors critical for myogenesis) with the potent transactivation domain of FOXO1 (a forkhead family transcription factor). The resultant chimeric proteins are constitutively active transcription factors that drive oncogenesis by activating proliferative programs while simultaneously blocking terminal myogenic differentiation (PMID: 10534762).

Comprehensive genomic analysis of 147 tumor/normal pairs demonstrated that: "Two genotypes are evident in rhabdomyosarcoma tumors: those characterized by the PAX3 or PAX7 fusion and those that lack these fusions but harbor mutations in key signaling pathways. The overall burden of somatic mutations in rhabdomyosarcoma is relatively low, especially in tumors that harbor a PAX3/7 gene fusion" (PMID: 24436047).

Risk Factors

Genetic Risk Factors

• Li-Fraumeni syndrome (TP53 germline mutations): A retrospective French cohort of 31 patients with Li-Fraumeni-associated RMS found a median age at diagnosis of 2.3 years, with anaplasia reported in 12/16 reviewed cases. The 10-year cumulative risk of second malignancies was 40%, strongly influencing long-term prognosis (PMID: 32658383).
• Beckwith-Wiedemann syndrome (11p15.5 abnormalities, IGF2 overexpression)
• Neurofibromatosis type 1 (NF1 mutations)
• Costello syndrome (HRAS mutations)
• Noonan syndrome (RAS-MAPK pathway mutations)
• DICER1 syndrome: Xeroderma pigmentosum group C patients with somatic DICER1 mutations have been reported to develop early-onset gynecological rhabdomyosarcomas (PMID: 37567969).
• Germline predisposition to genitourinary RMS has been documented across multiple genetic syndromes (PMID: 33209717).

Environmental Risk Factors

• Parental drug use (particularly cocaine and marijuana use during pregnancy — limited evidence)
• Prenatal X-ray exposure (historical association, limited modern data)
• Age: Peak incidence in childhood (ages 1–9), with a smaller peak in adolescence
• Sex: Slight male predominance in overall RMS
• No strong occupational or dietary environmental risk factors have been definitively established for ARMS

Protective Factors

No well-established genetic or environmental protective factors have been identified for ARMS. The rarity of the disease and its strong genetic basis (somatic translocations) limit the identification of modifiable protective factors.

Gene-Environment Interactions

Limited data exist on gene-environment interactions in ARMS. The disease appears to be predominantly driven by somatic genetic events rather than environmental exposures. However, in the context of cancer predisposition syndromes (e.g., Li-Fraumeni), the 10-year cumulative risk of second malignancies of 40% emphasizes the need to "reduce, whenever possible, the burden of genotoxic drugs and radiotherapy in carriers" (PMID: 32658383).

3. Phenotypes

Clinical Presentation

ARMS presents as a rapidly growing, often painless mass in various anatomical locations. The clinical phenotype depends on the primary tumor site.

Phenotype Characteristics

• Age of onset: Predominantly childhood, with peak incidence between ages 1–9 years; a secondary smaller peak in adolescence (15–19 years). Median age varies by site (e.g., median 3.5 years for parameningeal ARMS, PMID: 32044412).
• Symptom progression: Rapidly progressive; tumors typically grow over weeks to months.
• Symptom severity: Variable, ranging from an incidental finding to life-threatening mass effect depending on anatomical location.
• Frequency of metastatic disease at presentation: Approximately 23–27% of ARMS patients present with stage IV (metastatic) disease (PMID: 41524542; PMID: 40790568).

Quality of Life Impact

ARMS and its treatment significantly impact quality of life through: - Treatment-related toxicities (chemotherapy-induced nausea, immunosuppression, growth impairment) - Surgery-related morbidity (resection-related impairment in 33% of surviving infants, PMID: 30762282) - Long-term toxicity in 21% of survivors - Secondary malignancies in 6% of long-term survivors - Psychosocial burden on patients and families

4. Genetic/Molecular Information

Causal Genes and Chromosomal Abnormalities

"The PAX3-FOXO1 and PAX7-FOXO1 gene fusions occur in 80% of cases with the alveolar subtype and are more predictive of outcome than histologic classification" (PMID: 28058850).

Gene amplification studies have revealed that "Studies of the pediatric soft tissue cancer alveolar rhabdomyosarcoma have contributed to the current understanding of the diverse set of molecular changes that occur as part of the gene amplification process" (PMID: 41828638).

Pathogenic Variants

• Somatic origin: The PAX3-FOXO1 and PAX7-FOXO1 fusions are somatic events (not inherited).
• Variant type: Chromosomal translocations producing in-frame fusion genes.
• Functional consequence: Gain-of-function — the fusion proteins are constitutively active transcription factors with stronger transactivation than wild-type PAX3/PAX7.
• Additional recurrent mutations (from COSMIC/TCGA): NRAS, KRAS, HRAS, FGFR4, PIK3CA, CTNNB1, FBXW7, BCOR.
• Mutation burden: Low overall somatic mutation burden in fusion-positive tumors (PMID: 24436047).

Modifier Genes

• TBX2: Highly upregulated in both RMS subtypes; functions as an oncogene by blocking myogenic differentiation and promoting proliferation. TBX2 interacts with MyoD and myogenin, recruits HDAC1, and represses p21 and p14. "Depletion or interference with TBX2 completely inhibits tumor growth in a xenograft assay, highlighting the oncogenic role of TBX2 in RMS cells" (PMID: 24470334).
• SNAI2: Highly expressed in fusion-negative RMS; blocks myogenic differentiation by competing with MYOD at enhancers. RAS/MEK signaling modulates SNAI2 levels (PMID: 33420019).

Epigenetic Information

PAX3-FOXO1 drives oncogenesis through extensive epigenetic reprogramming: - Super enhancer activation: PAX3-FOXO1 activates super enhancers (SEs) to induce expression of core regulatory (CR) transcription factors. "In alveolar rhabdomyosarcoma, PAX3-FOXO1 activates SEs to induce the expression of other CR TFs, providing a model system for studying cancer cell addiction to CR transcription" (PMID: 31285436). - HDAC involvement: HDAC1/2/3 are co-essential isoforms that maintain core regulatory transcription; their co-inhibition halts CR transcription and disrupts chromatin looping. - DNA methylation: Aberrant methylation patterns associated with fusion-positive tumors have been used for epigenetic classification; cutaneous epithelioid/pleomorphic RMS can be distinguished from melanoma by DNA methylation profiling (PMID: 41780801).

Chromosomal Abnormalities

• t(2;13)(q35;q14): PAX3-FOXO1 fusion (most common)
• t(1;13)(p36;q14): PAX7-FOXO1 fusion (variant translocation)
• Gene amplification at 2p24: MYCN amplification
• Gene amplification at 12q13-15: CDK4 and MDM2 co-amplification
• PAX7-FOXO1 amplification: Sometimes amplified in the alveolar subtype (PMID: 10534762)
• Gains of chromosomes 2, 8, 12, 13: More commonly associated with ERMS

5. Environmental Information

Environmental Factors

No strong environmental causative factors have been definitively established for ARMS. Unlike many adult cancers, pediatric ARMS does not have well-documented associations with: - Occupational exposures - Toxic chemical exposure - Radiation exposure (though prenatal radiation has been historically suggested)

Lifestyle Factors

Given the pediatric nature of ARMS, lifestyle factors are largely not applicable. Parental exposures (maternal/paternal) during the periconceptional period and pregnancy have been investigated, but no definitive associations have been established.

Infectious Agents

No infectious agents have been causally linked to ARMS. This distinguishes ARMS from some other pediatric cancers (e.g., Burkitt lymphoma/EBV).

6. Mechanism / Pathophysiology

Molecular Pathways

The central pathophysiological mechanism of ARMS involves the PAX3-FOXO1 (or PAX7-FOXO1) fusion oncoprotein acting as an aberrant transcription factor that disrupts normal myogenic development.

Causal Chain: From Translocation to Clinical Disease

Somatic translocation t(2;13) or t(1;13)
 ↓
PAX3-FOXO1 / PAX7-FOXO1 fusion protein expressed
 ↓
Fusion protein binds PAX3/7 target genes with enhanced transactivation
 ↓
├── Activation of super enhancers → CR TF network activation
├── FGFR4 transcriptional activation → RTK signaling
├── Block of terminal myogenic differentiation (MyoD/Myogenin dysfunction)
├── Promotion of cell survival (anti-apoptotic programs)
└── Activation of proliferative signaling cascades
 ↓
RTK/RAS/PIK3CA axis hyperactivation (93% of cases)
 ↓
Uncontrolled proliferation of myogenic precursor cells
 ↓
Tumor formation, invasion, and metastasis

Key Signaling Pathways

"Alteration of the receptor tyrosine kinase/RAS/PIK3CA axis affects 93% of cases, providing a framework for genomics-directed therapies that might improve outcomes for patients with rhabdomyosarcoma" (PMID: 24436047).

Cellular Processes

• Differentiation block (GO:0030154): The fusion protein prevents terminal myogenic differentiation despite expression of myogenic master regulators (MYOD, MYOG). TBX2 contributes by interacting with MyoD/myogenin and repressing differentiation genes (PMID: 24470334).
• Cell cycle dysregulation (GO:0007049): Repression of p21 (CDKN1A) and p14 (CDKN2A) by TBX2 and the fusion protein promotes uncontrolled proliferation.
• Apoptosis evasion (GO:0006915): Enhanced cell survival through PI3K/AKT signaling.
• Invasion and metastasis (GO:0042060): ARMS has a high propensity for lymphatic and hematogenous metastasis, particularly to lungs, bone marrow, and bone.

Protein Dysfunction

• PAX3-FOXO1: Gain-of-function chimeric protein; constitutively active transcription factor with the DNA-binding specificity of PAX3 and the strong transactivation domain of FOXO1.
• FGFR4: Overexpressed and constitutively activated in FP-RMS; acts as a direct transcriptional target of PAX3-FOXO1. "We highlight the utility of FGFR inhibitors in PAX3-FOXO1 fusion-positive rhabdomyosarcomas characterized by high FGFR4 and FGF8 RNA expression levels and FGFR4 activation" (PMID: 42041178).

Immune System Involvement

• The tumor microenvironment in RMS is generally immunosuppressive.
• CD3E and CD8A expressions are significantly upregulated in rhabdomyosarcoma compared to other sarcomas, "showing the nature of immune-active tumor" (PMID: 33095470).
• Despite T-cell infiltration, effective anti-tumor immunity is limited by immunosuppressive mechanisms.
• Multiple immunotherapy approaches are under investigation, including CAR-T cells targeting HER2, CD276, FGFR4, PDGFR-α, and EphA2 (PMID: 41709231; PMID: 39763064).

Epigenetic Mechanisms

The super enhancer-mediated transcriptional program driven by PAX3-FOXO1 represents a critical epigenetic vulnerability: - HDAC1/2/3 co-inhibition disrupts core regulatory transcription by making CR TF sites hyper-accessible and disrupting chromatin looping (PMID: 31285436). - Entinostat (class I HDAC inhibitor) "transcriptionally suppresses the PAX3:FOXO1 tumor-initiating fusion gene found in alveolar rhabdomyosarcoma" (PMID: 31113472).

Natural Compounds Targeting ARMS Pathways

Natural compounds including curcumin, resveratrol, quercetin, epigallocatechin-3-gallate, and berberine have been shown to inhibit NF-κB signaling in rhabdomyosarcoma cells through various mechanisms, such as inhibiting the activation of the IKK complex and the NF-κB transcription factor (PMID: 37569275).

GO Terms for Key Biological Processes

• GO:0007517 — muscle organ development
• GO:0030154 — cell differentiation
• GO:0008283 — cell population proliferation
• GO:0006915 — apoptotic process
• GO:0016055 — Wnt signaling pathway
• GO:0007169 — transmembrane receptor protein tyrosine kinase signaling pathway
• GO:0042060 — wound healing / cell migration

Cell Types Involved (CL Terms)

• CL:0000515 — skeletal muscle myoblast (cell of origin)
• CL:0002372 — myogenic precursor cell
• CL:0000188 — cell of skeletal muscle

7. Anatomical Structures Affected

Organ Level

Primary sites:

"Patients with pelvic tumors had significantly higher mortality risk (hazard ratio = 1.44, 95%-confidence interval: 1.08-1.94, p = 0.014)" (PMID: 41709728).

Nasal and paranasal sinus ARMS exhibit particularly aggressive biology: "Nasal and paranasal sinus rhabdomyosarcoma were predominantly alveolar, large, distant spread, and with the highest proportion of affected lymph nodes" (PMID: 40188643).

Secondary organ involvement (metastatic sites): - Lungs (UBERON:0002048) - Bone marrow (UBERON:0002371) - Bone (UBERON:0002481) - Lymph nodes (UBERON:0000029) - Central nervous system (UBERON:0001017) — particularly leptomeningeal spread from parameningeal primaries. All 7 patients with distant metastases as first recurrence in a parameningeal ARMS cohort had CNS metastases (PMID: 32044412).

Tissue and Cell Level

• Tissue: Skeletal muscle tissue (UBERON:0001134)
• Cell populations: Skeletal muscle myoblasts (CL:0000515), myogenic precursor cells (CL:0002372)
• The tumor cells express myogenic markers (desmin, MyoD1, myogenin) confirming skeletal muscle lineage

Subcellular Level

• Nucleus (GO:0005634): Site of PAX3-FOXO1 transcriptional activity; super enhancer activation
• Chromatin (GO:0000785): Epigenetic remodeling by HDACs and fusion protein
• Cytoplasm (GO:0005737): RTK/RAS/PI3K signaling cascades

Localization

• Primary tumors can arise in virtually any anatomical location with skeletal muscle or mesenchymal tissue.
• No consistent lateralization; tumors are typically unilateral.
• Specific anatomical sites carry distinct prognoses, as detailed in the organ-level table above.

8. Temporal Development

Onset

• Typical age of onset: Predominantly pediatric, with peak incidence between 1–9 years; secondary peak in adolescence (15–19 years). Median age varies by site and cohort (e.g., 4.1 years for group I ARMS, PMID: 32124549; 6 years for extremity RMS, PMID: 10693687).
• Onset pattern: Typically subacute to chronic; presenting as a growing mass over weeks to months.
• Infants (≤12 months): 155 patients registered in the CWS between 1981–2016; 23/25 examined ARMS patients were PAX7/3:FOXO1-positive (PMID: 30762282).

Progression

Staging: Uses both the IRSG (Intergroup Rhabdomyosarcoma Study Group) Clinical Grouping system (Groups I–IV based on surgical completeness) and the TNM-based preoperative staging system.

(PMID: 10693687)

• Progression rate: Rapid; ARMS is an aggressive, fast-growing tumor with high metastatic potential.
• Disease course: Progressive without treatment; relapse is common in high-risk disease.
• Median time to relapse: 0.5 years from initial treatment (range 0.2–2.1 years) for parameningeal ARMS (PMID: 32044412).

Patterns

• Relapse pattern: 63% of infants with ARMS suffered relapse, compared to 28% of ERMS patients (PMID: 30762282).
• Post-relapse prognosis: After first relapse/progression, 3-year OS is only 8% (PMID: 41721480).
• Critical period: Early detection and complete surgical resection are critical for long-term survival.

9. Inheritance and Population

Epidemiology

• Incidence: RMS overall: approximately 4.5 per 1,000,000 children per year; ARMS represents ~20–25% of these cases.
• Prevalence: Rare; exact prevalence figures are limited due to the aggressive nature of the disease.
• SEER data: A population-based analysis identified 1,114 head/neck RMS cases from SEER17 (2000–2020), with 5-year OS of 59.1% (PMID: 40188643).

Genetic Etiology

• Inheritance pattern: ARMS is predominantly a sporadic disease caused by somatic translocations. It is not inherited in the classical Mendelian sense.
• Cancer predisposition syndromes: A minority of cases occur in the context of hereditary cancer predisposition syndromes:
• Li-Fraumeni syndrome (TP53, autosomal dominant, incomplete penetrance)
• Beckwith-Wiedemann syndrome (11p15.5, imprinting disorder)
• Costello syndrome (HRAS, autosomal dominant)
• Noonan syndrome (RAS-MAPK pathway)
• Penetrance/Expressivity: Not directly applicable as ARMS is a somatic disease. For germline predisposition syndromes, penetrance for RMS specifically is incomplete and age-dependent.
• No founder effects, consanguinity associations, or carrier frequency are relevant, as the disease arises from somatic mutations.

Population Demographics

• Sex ratio: Slight male predominance overall in RMS; specific ratios vary by study (e.g., 71.4% male in an orbital RMS cohort, PMID: 40719714; 54.2% female in a Rwandan cohort, PMID: 41524542).
• Geographic distribution: Worldwide distribution; outcomes differ dramatically between high-income and low-income settings. In Uganda, 5-year OS was only 35% with 46.1% treatment abandonment (PMID: 40790568).
• Ethnic/racial variation: Data are limited; no strong racial predisposition has been firmly established.
• Age distribution: Bimodal, with primary peak in early childhood (1–9 years) and secondary peak in adolescence.

10. Diagnostics

Clinical Tests

Laboratory Tests and Biomarkers

• Serum LDH: Elevated LDH above 400 U/L at diagnosis is a significant prognostic factor (HR=2.80, 95% CI 1.46–5.33, p=0.002) (PMID: 40790568).
• PAX3-FOXO1 / PAX7-FOXO1 fusion status: The most important diagnostic and prognostic biomarker.
• Complete blood count, metabolic panel: Routine baseline evaluation.

Imaging Studies

Biopsy and Histopathology

• Histological pattern: Small round blue cells arranged in nests separated by fibrovascular septa (alveolar pattern); solid variant also exists.
• Immunohistochemistry (IHC):
• Desmin: Positive (diffuse)
• MyoD1: Positive
• Myogenin: Positive (often diffuse and strong in ARMS, distinguishing from ERMS)
• Vimentin: Positive
• Sarcomeric actin: Variable

Genetic Testing

• FISH: For FOXO1 rearrangement — the primary cytogenetic test. Confirmed utility in multiple studies (PMID: 36719455).
• RT-PCR: Detection of PAX3-FOXO1 and PAX7-FOXO1 fusion transcripts.
• Next-generation sequencing (NGS): Comprehensive genomic profiling for fusion detection, mutation analysis, and gene amplification assessment. Fusion panel sequencing (e.g., Archer FusionPlex assay) can detect canonical and non-canonical fusions.
• Karyotyping: Can identify characteristic translocations t(2;13) and t(1;13).

The SIOP Asia congress emphasized "molecularly driven diagnostics such as FOXO1 fusion testing in rhabdomyosarcoma" with emphasis on affordable applications in low-resource settings (PMID: 41962056).

Clinical Criteria and Differential Diagnosis

Differential diagnosis:

Screening

No population-based screening programs exist for ARMS. Surveillance in cancer predisposition syndromes (Li-Fraumeni, Beckwith-Wiedemann, Costello syndrome) may allow earlier detection.

11. Outcome/Prognosis

Survival and Mortality

Overall Survival by Stage and Fusion Status

"Among nonmetastatic patients, patients who were PAX3/FOXO1 positive had a significantly poorer outcome compared with both alveolar-negative and PAX7/FOXO1-positive patients" (PMID: 22454413).

"With a median follow-up of 2.9 years, the 3-year event-free survival rate was 16%" for metastatic RMS treated with cixutumumab addition (PMID: 30351457).

The INSTRuCT consortium analysis of 1,095 M1 RMS patients found "5-year Overall and Event Free Survival were 32.0% (95% CI 29.2-34.9) and 27.5% (95% CI 24.8-30.2) respectively" (PMID: 41721480).

Prognostic Factors

Morbidity and Complications

• Treatment-related: Chemotherapy toxicity (hematologic, gastrointestinal), radiation late effects, surgical disfigurement
• Disease-related: Organ dysfunction from tumor invasion, pain, metastatic complications
• Long-term survivors: Secondary malignancies (6%), long-term organ toxicity (21%), resection-related impairment (33%) (PMID: 30762282)

12. Treatment

Pharmacotherapy (MAXO:0000058 — chemotherapy)

Standard Chemotherapy

"For more than three decades, standard treatment for rhabdomyosarcoma in Europe has included 6 months of chemotherapy. The European paediatric Soft tissue sarcoma Study Group aimed to investigate whether prolonging treatment with maintenance chemotherapy would improve survival" — the EpSSG RMS 2005 trial demonstrated 5-year DFS of 77.6% with maintenance vinorelbine/cyclophosphamide in high-risk patients (PMID: 31562043).

As reviewed comprehensively: "Although the gene fusions PAX3::FOXO1 and PAX7::FOXO1 were discovered in the early 1990s... the best treatment to date still remains VAC combination therapy, first instituted as standard of care in the 1970s" (PMID: 41038289).

Targeted Therapies (MAXO:0001525 — targeted therapy)

• FGFR inhibitors: Emerging utility in PAX3-FOXO1-positive RMS with high FGFR4 expression (PMID: 42041178).
• HDAC inhibitors (Entinostat): Class I HDAC inhibitor that transcriptionally suppresses PAX3-FOXO1; being investigated as combinatorial therapy (PMID: 31113472; PMID: 39147820).
• IGF1R inhibitors (Cixutumumab): Tested in COG ARST08P1 but did not improve outcomes (PMID: 30351457).
• Metformin + VIT: Phase I trial established safety; one partial response in ARMS (PMID: 36151773).

Immunotherapy (MAXO:0001298 — immunotherapy)

• CAR-T cells: Targeting HER2, CD276, FGFR4, PDGFR-α, and EphA2. "We explore the potential of CAR-T cell therapy as a transformative approach for rhabdomyosarcoma, focusing on target antigens such as HER2, CD276, FGFR4, PDGFR-α, and others" (PMID: 41709231).
• CAR-NK cells: EphA2-targeted CAR-NK cells demonstrated enhanced cytotoxicity against RMS cell lines in vitro and anti-tumor activity in mouse models (PMID: 39763064).
• Bispecific T-cell engagers (BiTEs) and antibody peptide epitope conjugates (APECs): Tested in immunodeficient zebrafish xenograft models with real-time visualization (PMID: 34415995).
• EGFR-targeted immunotherapies: Established as a promising approach for RMS in preclinical zebrafish models, "providing strong preclinical rationale for assessing a wider array of T cell immunotherapies in this disease" (PMID: 34415995).
• Immune checkpoint inhibitors: Under investigation; limited single-agent activity to date (PMID: 31311607; PMID: 26301204).

Surgery (MAXO:0000004 — surgical procedure)

• Complete surgical resection (when feasible without functional loss) is critical for outcome.
• Group I (complete resection): 3-year FFS ~91% vs. Group III (gross residual): ~50% (PMID: 10693687).
• Sentinel lymph node biopsy recommended for extremity RMS to ensure accurate staging.
• In infants, microscopically complete resection is strongly recommended for both primary and relapsed disease (PMID: 30762282).

Radiation Therapy (MAXO:0000014 — radiation therapy)

• Adjuvant RT (36–50.4 Gy) is standard for most ARMS patients.
• For FOXO1-positive group I ARMS: RT significantly improved EFS (77.8% vs 16.7%, p=0.03) (PMID: 32124549).
• For FOXO1-negative ARMS after complete resection: omitting RT is rational and being prospectively investigated (PMID: 32124549).
• Proton therapy preferred for parameningeal tumors to minimize late effects.

Treatment Strategy

The treatment algorithm is risk-stratified based on: 1. Fusion status (FOXO1-positive vs negative) 2. Clinical Group (I–IV) 3. TNM stage 4. Age and tumor size

MAXO terms applicable: - MAXO:0000058 — chemotherapy - MAXO:0000004 — surgical procedure - MAXO:0000014 — radiation therapy - MAXO:0001298 — immunotherapy - MAXO:0001525 — targeted therapy

13. Prevention

Primary Prevention

No primary prevention strategies exist for ARMS. The disease arises from somatic chromosomal translocations that cannot be prevented.

Secondary Prevention (Early Detection)

• No population-based screening programs exist for ARMS.
• In cancer predisposition syndromes (Li-Fraumeni, Beckwith-Wiedemann, Costello, Noonan), surveillance protocols may include regular physical examinations and imaging.
• "Anaplastic RMS in childhood, independently of the familial history, should lead to TP53 analysis at treatment initiation" (PMID: 32658383).

Tertiary Prevention

• Surveillance for disease recurrence during and after treatment
• Monitoring for treatment-related late effects (cardiotoxicity, infertility, secondary malignancies)
• In Li-Fraumeni patients: "ensure the early detection of second malignancies" with reduced genotoxic therapy burden (PMID: 32658383)

Genetic Counseling (MAXO:0000079)

• Recommended for families with cancer predisposition syndromes
• TP53 testing should be considered for ARMS patients with anaplastic features or family cancer history
• Germline predisposition screening for genitourinary RMS patients (PMID: 33209717)

14. Other Species / Natural Disease

Natural Disease in Animals

• Brook trout (Salvelinus fontinalis): A spontaneously arising rhabdomyosarcoma of soft tissues was described in a brook trout, "diagnosed as solid alveolar rhabdomyosarcoma of soft tissues on the basis of histological and ultrastructural findings" — the lesion showed 'small round cell' morphology with rare myotube formation, positive for sarcomeric actin and vimentin (PMID: 26072379).
• NCBI Taxon: 8038 (Salvelinus fontinalis)

Comparative Biology

• The conservation of myogenic regulatory factors (MyoD, Myogenin) across vertebrates allows ARMS-like tumors to arise in diverse species.
• Cross-species IHC cross-reactivity was limited: desmin, MyoD1, myogenin, and CD3 were negative in the fish tumor, likely due to low protein sequence identity.
• Zebrafish (Danio rerio, NCBI Taxon: 7955) serve as important xenograft models for studying human ARMS in vivo (PMID: 31031007).

Orthologous Genes

Zoonotic Potential

Not applicable. ARMS is not an infectious disease and has no zoonotic potential.

15. Model Organisms

Mouse Models

Zebrafish Models

• Immunodeficient zebrafish (prkdc-/-): Optically clear models enabling real-time single-cell visualization of human ARMS xenografts and immunotherapy responses. These "optically-clear prkdc" mutant zebrafish allow engraftment of fluorescent-labeled human cancers (PMID: 31031007).
• Applications include testing CAR-T cells, BiTEs, APECs, and targeted therapies with real-time imaging. This work "uncovered important differences in the kinetics of T cell infiltration, tumor cell engagement, and killing between these immunotherapies and established early endpoint analysis to predict therapy responses" (PMID: 34415995).

Cell Line Models

Model Limitations

• Mouse models: Conditional PAX3-FOXO1 expression alone is insufficient for tumorigenesis; cooperating events (p53 loss, Ink4a/Arf deletion) are required, which may not fully reflect human disease initiation.
• Zebrafish xenografts: Species-specific differences in microenvironment; short duration of engraftment experiments.
• Cell lines: Extended in vitro culture may introduce artifacts; clonal selection over passages.

Key Findings

Finding 1: ARMS Is Driven by PAX3-FOXO1 or PAX7-FOXO1 Gene Fusions

The hallmark molecular feature of ARMS is the presence of recurrent chromosomal translocations producing PAX3-FOXO1 (t(2;13)(q35;q14)) or PAX7-FOXO1 (t(1;13)(p36;q14)) fusion oncogenes in approximately 80% of cases. These fusion proteins serve as the primary oncogenic drivers, functioning as constitutively active transcription factors with the DNA-binding specificity of PAX3/7 and the potent transactivation domain of FOXO1. Comprehensive genomic analysis of 147 tumor/normal pairs confirmed that fusion-positive tumors have a remarkably low overall somatic mutation burden, indicating that the fusion oncoprotein is sufficient to drive the majority of the oncogenic program. Critically, the specific fusion type carries prognostic significance: PAX3-FOXO1-positive patients have significantly worse outcomes than both PAX7-FOXO1-positive and fusion-negative patients (PMID: 28058850; PMID: 22454413; PMID: 24436047).

Finding 2: The RTK/RAS/PIK3CA Axis Is Altered in 93% of Rhabdomyosarcomas

Comprehensive genomic analysis revealed that the receptor tyrosine kinase/RAS/PIK3CA signaling axis is altered in 93% of all RMS cases, encompassing recurrent mutations in NRAS, KRAS, HRAS, FGFR4, PIK3CA, CTNNB1, FBXW7, and BCOR. In fusion-positive ARMS, FGFR4 is particularly relevant as it is a direct transcriptional target of the PAX3-FOXO1 fusion and is both overexpressed and constitutively activated. This near-universal pathway alteration provides a framework for genomics-directed therapies, with FGFR inhibitors showing particular promise in FP-RMS characterized by high FGFR4 and FGF8 expression (PMID: 24436047; PMID: 42041178).

Finding 3: PAX3-FOXO1 Activates Super Enhancers to Drive Core Regulatory Transcription

The PAX3-FOXO1 fusion protein exerts its oncogenic effects in large part through epigenetic reprogramming, specifically by activating super enhancers that induce expression of core regulatory transcription factors. This creates a "transcriptional addiction" that can be therapeutically exploited. HDAC1/2/3 are co-essential enzymes maintaining this program; their co-inhibition halts core regulatory transcription, makes CR TF sites hyper-accessible, and disrupts chromatin looping. The class I HDAC inhibitor entinostat transcriptionally suppresses PAX3-FOXO1 expression, providing a pharmacological strategy to target the upstream driver (PMID: 31285436; PMID: 31113472).

Finding 4: Metastatic ARMS Has Extremely Poor Prognosis

Metastatic ARMS remains one of the most difficult-to-cure pediatric cancers. The COG ARST08P1 trial (168 patients, 70% alveolar histology) demonstrated a 3-year EFS of only 16% despite intensive multiagent chemotherapy with cixutumumab addition. The INSTRuCT consortium analysis of 1,095 M1 RMS patients showed 5-year OS of 32% and 5-year EFS of 27.5%, with post-relapse 3-year OS plummeting to only 8%. Pelvic primary site independently predicted worse outcomes (HR=1.44, p=0.014) (PMID: 30351457; PMID: 41721480; PMID: 41709728).

Finding 5: Maintenance Chemotherapy Improves Outcomes in High-Risk RMS

The EpSSG RMS 2005 phase 3 trial (371 patients randomized) demonstrated that maintenance chemotherapy with vinorelbine (25 mg/m² IV) and continuous low-dose oral cyclophosphamide for 6 cycles improved 5-year DFS to 77.6% in high-risk patients, including non-metastatic alveolar RMS. This landmark trial established maintenance therapy as a new standard of care for high-risk RMS in Europe (PMID: 31562043).

Mechanistic Model / Interpretation

The pathogenesis of ARMS can be understood as a multi-level disruption of normal myogenic development:

LEVEL 1: INITIATING EVENT
═══════════════════════════
Somatic chromosomal translocation → PAX3-FOXO1 or PAX7-FOXO1 fusion

LEVEL 2: TRANSCRIPTIONAL REPROGRAMMING
═══════════════════════════════════════
Fusion protein → Super enhancer activation → CR TF network
→ FGFR4 overexpression
→ Block of MYOD/MYOG differentiation targets
→ TBX2 upregulation → p21/p14 repression

LEVEL 3: SIGNALING CASCADE ACTIVATION
═════════════════════════════════════
RTK/RAS/PIK3CA axis (93% altered)
├── FGFR4 → RAS → MAPK → proliferation
├── PI3K → AKT → mTOR → survival/growth
├── NF-κB → inflammation/survival
└── IGF1R → PI3K → survival

LEVEL 4: CELLULAR CONSEQUENCES
══════════════════════════════
├── Proliferation without differentiation
├── Apoptosis resistance
├── Enhanced motility and invasion
└── Immune evasion

LEVEL 5: CLINICAL DISEASE
═════════════════════════
├── Rapidly growing soft tissue mass
├── High metastatic potential (lungs, bone marrow, bone)
├── Treatment resistance (especially metastatic/relapsed)
└── Poor prognosis without multimodal therapy

The identification of super enhancer-mediated transcriptional addiction as a central vulnerability offers the most promising therapeutic avenue: HDAC inhibitors (entinostat) can suppress the fusion gene itself, while FGFR inhibitors can target its key downstream effector. The combination of these approaches with conventional chemotherapy and emerging immunotherapies represents the most rational strategy for improving outcomes.

Evidence Base

Landmark Papers

Supporting Literature by Topic

• Diagnostics and imaging: PMID: 41734302 (ultrasound discrimination ARMS vs non-ARMS)
• Site-specific prognosis: PMID: 40188643 (head/neck subsites); PMID: 41709728 (pelvic ARMS); PMID: 41498078 (extremity); PMID: 41666515 (lymph node involvement)
• Radiation therapy: PMID: 32124549 (RT in group I ARMS); PMID: 32044412 (parameningeal patterns of failure)
• Immunotherapy: PMID: 41709231 (CAR-T review); PMID: 39763064 (EphA2 CAR-NK cells); PMID: 34415995 (zebrafish immunotherapy models); PMID: 31311607 (immunotherapy trends)
• Cancer predisposition: PMID: 32658383 (Li-Fraumeni); PMID: 33209717 (GU germline predisposition); PMID: 37567969 (XP-C)
• Molecular biology: PMID: 24470334 (TBX2); PMID: 33420019 (SNAI2-MYOD); PMID: 31113472 (entinostat); PMID: 39147820 (entinostat combination)
• Global outcomes: PMID: 41524542 (Rwanda); PMID: 40790568 (Uganda)

Limitations and Knowledge Gaps

1. Fusion-negative ARMS: Approximately 20% of histologically alveolar RMS tumors lack PAX3/7-FOXO1 fusions. These "fusion-negative alveolar" tumors biologically behave more like ERMS and are now recognized as a distinct entity, but their molecular drivers remain incompletely understood.

2. Therapeutic resistance mechanisms: The molecular basis of chemotherapy resistance in relapsed/metastatic ARMS is poorly understood. Why post-relapse 3-year OS is only 8% despite salvage therapy is not fully explained.

3. Limited clinical trial data for ARMS-specific subgroups: Most clinical trials enroll all RMS subtypes together, making it difficult to determine ARMS-specific treatment effects.

4. Immunotherapy challenges: Despite promising preclinical data, CAR-T cell therapy faces significant hurdles in ARMS including antigen heterogeneity, immunosuppressive tumor microenvironment, and manufacturing challenges (PMID: 41709231).

5. Lack of validated liquid biopsy markers: Circulating biomarkers for early detection, monitoring, and minimal residual disease assessment are not yet clinically validated.

6. Low-resource settings: Treatment outcomes in low-income countries remain dramatically worse (5-year OS ~35% in Uganda vs. ~70% in high-income settings), driven by late diagnosis, treatment abandonment, and limited access to multimodal therapy (PMID: 40790568).

7. Gene-environment interactions: Virtually no data exist on modifiable risk factors or gene-environment interactions in ARMS pathogenesis.

8. Epigenetic heterogeneity: The extent of intra-tumoral epigenetic heterogeneity and its role in treatment resistance is not well characterized.

Proposed Follow-up Experiments/Actions

1. FGFR4-targeted clinical trials: Based on the strong preclinical rationale (PMID: 42041178), prospective trials of FGFR inhibitors (e.g., erdafitinib, futibatinib) in PAX3-FOXO1-positive ARMS with confirmed FGFR4 activation should be prioritized. Patient stratification by FGFR4 expression and phosphorylation status is essential.

2. Entinostat combination strategies: Given that entinostat suppresses PAX3-FOXO1 expression and disrupts super enhancer-mediated transcription (PMID: 31113472; PMID: 39147820), phase I/II trials combining entinostat with standard chemotherapy (VAC) or targeted agents (FGFR inhibitors) should be conducted.

3. Multi-antigen CAR-T cell therapies: To overcome antigen heterogeneity, dual- or multi-targeting CAR-T cells (e.g., FGFR4 + CD276, or EphA2 + HER2) should be developed and tested. Combination with checkpoint blockade may enhance efficacy.

4. Circulating tumor DNA (ctDNA) biomarker development: Detection of PAX3-FOXO1 fusion transcripts in plasma could serve as a minimally invasive tool for diagnosis, monitoring, and minimal residual disease detection.

5. Single-cell multi-omics of ARMS: Comprehensive single-cell RNA-seq, ATAC-seq, and spatial transcriptomics of treatment-naive and relapsed ARMS tumors would illuminate cellular heterogeneity, resistance mechanisms, and immune microenvironment dynamics.

6. Global access initiatives: Adapting diagnostic and treatment protocols for low-resource settings, including affordable FOXO1 FISH testing and simplified chemotherapy regimens, could significantly improve outcomes in LMICs.

7. PAX3-FOXO1 protein degradation strategies: PROTACs (proteolysis targeting chimeras) or molecular glue degraders targeting the fusion protein directly represent a novel therapeutic strategy that warrants exploration.

8. Longitudinal immune monitoring: Prospective studies characterizing the immune microenvironment evolution during treatment and at relapse would inform rational immunotherapy combinations.

Report generated: 2026-05-05. This comprehensive disease knowledge base entry synthesizes evidence from 55 primary literature sources and established disease databases. All cited PMIDs have been verified against their abstracts for citation accuracy.